Apellis
APLS
Performance
About Apellis
Apellis is a global biopharmaceutical company developing life-changing therapies that target the complement system, focusing on diseases driven by excessive activation of the complement cascade. The company emphasizes C3-targeted therapies across areas such as hematology, ophthalmology, and nephrology, with a research and development pipeline spanning clinical trials and rare diseases. Headquartered with global reach, Apellis communicates a patient-centric mission and a commitment to advancing science in complement biology.
Recent News
Biogen Seals $5.3 B Deal for Apellis, Adds Two Blockbuster Drugs
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
With Growth Curve Trending up, Biogen Looks to Early-Stage Assets for ‘Next Generation’
Sobi Reports Health Canada Approval of Empaveli for C3G and Primary IC-MPGN
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
Goldman Sachs Sets New Biogen Stock Price Target on Bold Alzheimer's Bet
Top Biotech Deals in March 2026
Biogen, with $5.6B Apellis Buy, Builds Out Immunology Offerings
Pharmaceutical Executive Daily: Trump Administration Delays Appeal of Federal Ruling Blocking Vaccine Policy Overhaul
Early Intervention an Unmet Need in Diabetic Macular Edema
#58936
Roth/MKM Downgrades Apellis Stock Rating on Biogen Acquisition
InsideArbitrage Event Driven Monitor – April 1, 2026
Biogen to Acquire Apellis for $5.6 B, Shares Jump 136% on Deal
Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
100% Pharma Tariffs, Lilly's Oral GLP-1 Approval, and a $12B Week in Biotech M&A – This Week in Biotech #94
Apellis Pharmaceuticals (APLS) Hits 2-Year High on 140% Upside From Biogen Merger
After Apellis Deal, Biogen Looks to Fill Early-Stage Pipeline
The BioPharm Brief: Oncology Momentum, CAR-T Advances, Strategic Expansion
After BuzzFeed, Byron Allen Sets His Sights on Starz – Merger Arbitrage Mondays
Biogen Filing Reveals Apellis Deal Details; Telix Raises $600M